<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The use of oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy for the prevention of arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in patients who have had <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is controversial </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="23403">Coumarins</z:chebi> may increase the <z:mp ids='MP_0001914'>bleeding</z:mp> risk in patients with <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> of arterial origin </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVES: 1) To calculate incidence rates of <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> in patients with noncardiac <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> who were treated routinely in an anticoagulation clinic </plain></SENT>
<SENT sid="3" pm="."><plain>2) To assess which factors contribute to the occurrence of events </plain></SENT>
<SENT sid="4" pm="."><plain>3) To determine the optimal intensity of oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy in these patients </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: The authors studied <z:hpo ids='HP_0000001'>all</z:hpo> patients treated for noncardiac <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> at the Leiden anticoagulation clinic between 1993 and 1998 </plain></SENT>
<SENT sid="6" pm="."><plain>Outcome events were major <z:mp ids='MP_0001914'>hemorrhage</z:mp>, major arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The authors observed 356 patients for 644 patient-years </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of major <z:mp ids='MP_0001914'>hemorrhage</z:mp> was 3.9 per 100 patient-years (95% CI, 2.5 to 5.7) and that of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> was 3.0 per 100 patient-years (95% CI, 1.8 to 4.6) </plain></SENT>
<SENT sid="9" pm="."><plain>The incidence of <z:mp ids='MP_0001914'>hemorrhage</z:mp> varied with the duration of treatment (relative risk [RR] of the first versus the second half-year, 3.8; 95% CI, 1.9 to 7.6), age (RR for age &gt;65 years, 3.7; 95% CI, 1.1 to 12.3), and the intensity of oral anticoagulation (RR, 1.8 for each 0.5 international normalized ratio [INR] unit increase; 95% CI, 1.5 to 2.3) </plain></SENT>
<SENT sid="10" pm="."><plain>The optimal intensity of oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy was 2.5 to 3.5 INR; the best target value was 3.0 INR </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The risk of <z:mp ids='MP_0001914'>hemorrhage</z:mp> with <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy is high in patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> of arterial origin but is mainly confined to early use and elderly patients </plain></SENT>
</text></document>